Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
2.

Molecular alterations in prostate cancer and association with MRI features.

Lee D, Fontugne J, Gumpeni N, Park K, MacDonald TY, Robinson BD, Sboner A, Rubin MA, Mosquera JM, Barbieri CE.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):430-435. doi: 10.1038/pcan.2017.33. Epub 2017 Aug 1.

PMID:
28762374
3.

Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing.

Tewari AK, Ali A, Metgud S, Theckumparampil N, Srivastava A, Khani F, Robinson BD, Gumpeni N, Shevchuk MM, Durand M, Sooriakumaran P, Li J, Leung R, Peyser A, Gruschow S, Asija V, Harneja N.

World J Urol. 2013 Jun;31(3):471-80. doi: 10.1007/s00345-012-1018-7. Epub 2013 Jan 26.

PMID:
23354288
4.

Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques.

Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, Shariat SF.

BJU Int. 2012 Nov;110(10):1463-70. doi: 10.1111/j.1464-410X.2012.11129.x. Epub 2012 Apr 13. Review.

Supplemental Content

Loading ...
Support Center